Replimune Group Inc [REPL] stock is trading at $9.04, down -0.99%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The REPL shares have gain 5.36% over the last week, with a monthly amount glided 107.82%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Replimune Group Inc [NASDAQ: REPL] stock has seen the most recent analyst activity on November 03, 2025, when BMO Capital Markets upgraded its rating to a Market Perform but kept the price target unchanged to $11 for it. Previously, H.C. Wainwright upgraded its rating to Buy on October 27, 2025, and kept the price target unchanged to $12. On October 20, 2025, upgrade upgraded it’s rating to Outperform but maintained its price target of $18 on the stock. Piper Sandler upgraded its rating to a Overweight but stick to its price target of $13 on October 20, 2025. Leerink Partners upgraded its rating to a Outperform but $13 remained the price target by the analyst firm on October 20, 2025. JP Morgan upgraded its rating to Neutral for this stock on October 20, 2025. In a note dated September 19, 2025, JP Morgan downgraded an Underweight rating on this stock.
Replimune Group Inc [REPL] stock has fluctuated between $2.68 and $17.00 over the past year. Currently, Wall Street analysts expect the stock to reach $13.67 within the next 12 months. Replimune Group Inc [NASDAQ: REPL] shares were valued at $9.04 at the most recent close of the market. An investor can expect a potential return of 51.22% based on the average REPL price forecast.
Analyzing the REPL fundamentals
Gross Profit Margin for this corporation currently stands at -1.92% with Operating Profit Margin at -200.19%, Pretax Profit Margin comes in at -190.05%, and Net Profit Margin reading is -190.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -0.69 and Total Capital is -0.72. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.58 points at the first support level, and at 8.13 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.43, and for the 2nd resistance point, it is at 9.83.
Ratios To Look Out For
For context, Replimune Group Inc’s Current Ratio is 6.31. Also, the Quick Ratio is 6.31, while the Cash Ratio stands at 1.63.
Transactions by insiders
Recent insider trading involved Hill Emily Luisa, Chief Financial Officer, that happened on Aug 15 ’25 when 9154.0 shares were sold. Director, Astley-Sparke Philip completed a deal on May 20 ’25 to sell 32279.0 shares. Meanwhile, Chief Medical Officer Xynos Konstantinos sold 7952.0 shares on May 20 ’25.
